Develop CER Strategies, Or Be Left Behind, GSK Exec Says
Executive Summary
Execs from GlaxoSmithKline and OptumInsight offer insight on the need for pharma companies to develop strategies that account for the growing role comparative effectiveness research is playing in reforming health care, a role that will continue despite what happens in legal and legislative circles in Washington, D.C.
You may also be interested in...
Thirteen Principles For Conducting CER, According To United BioSource Exec
During a recent DIA-sponsored conference, United BioSource Corp.’s Bryan Luce previewed a paper that will outline 13 principles that should be taken into account when developing comparative effectiveness research.
PCORI In 2012: The Year Of Stakeholder Engagement
With a draft document containing the national priorities and research agenda now available for comment, PCORI will focus in 2012 on discussing with stakeholders what specific research should be funded. By the end of 2012 PCORI expects to have a portfolio of research activities under way.
Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.